Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Company News

FDA approves Jazz's Sunosi for daytime sleepiness

Brian Moy, Assistant Editor
March 21, 2019 12:20 AM UTC

FDA approved late Wednesday Sunosi solriamfetol from Jazz to improve wakefulness in adult patients with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea.

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) expects to launch Sunosi following a final scheduling decision by the U.S. Drug Enforcement Agency, which the company said is typically within 90 days of approval. Chairman and CEO Bruce Cozadd told BioCentury Sunosi's price will be disclosed at the time of launch...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

Jazz Pharmaceuticals plc